CID 9998128 | 733807-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: CID 9998128
• 英文别名: 4-(1H-indazol-5-ylamino)-2-(6-methylpyridin-2-yl)quinazoline；N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine；N-(1H-indazol-5-yl)-2-(6-methylpyridin-2-yl)quinazolin-4-amine
• CAS: 733807-13-1
• 化学式: C₂₁H₁₆N₆
• 分子量: 352.398
• InChiKey: HNHRWNUXTCATSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-methylpyridine-2-carboxylic acid (2-carbamoylphenyl)amide 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium hydroxide 、 sodium t-butanolate 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 27.0h， 生成 CID 9998128
  参考文献：
  名称：

  Dual Inhibition of Mycobacterium tuberculosis and the Host TGFBR1 by an Anilinoquinazoline

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c01273

文献信息

• [EN] CONDENSED PYRIDINES AND PYRIMIDINES AND THEIR USE AS ALK-5 RECEPTOR LIGANDS<br/>[FR] PYRIDINES ET PYRIMIDINES CONDENSEES ET LEUR UTILISATION EN TANT QUE LIGANDS DU RECEPTEUR ALK-5
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004065392A1

  公开（公告）日：2004-08-05

  Therapeutically active substituted quinoline and quinazoline compounds derivatives of formula (I) wherein X is N or CH, Y is NH, N (alkyl) or NH-CH2, and R2 and R3 are specified heterorings, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor β (TGF-β), and pharmaceutical compositions for use in such therapy are disclosed.

  治疗上有效的取代喹啉和喹唑啉化合物，其公式（I）中X是N或CH，Y是NH、N（烷基）或NH-CH2，R2和R3是特定的杂环，其在治疗中的用途，特别是在治疗或预防转化生长因子β（TGF-β）过度表达的疾病中的用途，以及用于此类治疗的药物组合物被披露。
• Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors
  作者：F. Gellibert、M.-H. Fouchet、V.-L. Nguyen、R. Wang、G. Krysa、A.-C. de Gouville、S. Huet、N. Dodic

  DOI：10.1016/j.bmcl.2009.02.087

  日期：2009.4

  Starting from quinazoline 3a, we designed potent and selective ALK5 inhibitors over p38MAP kinase from a rational drug design approach based on co-crystal structures in the human ALK5 kinase domain. The quinazoline 3d exhibited also in vivo activity in an acute rat model of DMN-induced liver fibrosis when administered orally at 5 mg/kg (bid). (c) 2009 Elsevier Ltd. All rights reserved.
• CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
  申请人：Sheridan Joseph M.

  公开号：US20140031547A1

  公开（公告）日：2014-01-30

  The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
• CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES
  申请人：Electrophoretics Limited

  公开号：US20160354375A1

  公开（公告）日：2016-12-08

  The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
• IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
  申请人：CAMP4 THERAPEUTICS CORPORATION

  公开号：US20210254056A1

  公开（公告）日：2021-08-19

  The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.